<DOC>
	<DOCNO>NCT01270165</DOCNO>
	<brief_summary>No study report comparative effect continue lamivudine plus adefovir versus switch telbivudine plus adefovir HBeAg-positive lamivudine-refractory chronic hepatitis B patient suboptimal response lamivudine plus adefovir . The goal study compare efficacy continue lamivudine plus adefovir versus switch telbivudine plus adefovir directly patient lamivudine-refractory chronic hepatitis B patient suboptimal response lamivudine plus adefovir least 12 month .</brief_summary>
	<brief_title>Lamivudine Plus Adefovir Versus Telbivudine Plus Adefovir Lamivudine Resistant Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HBeAg positive lamivudine adefovir least 12 month 6 month lamivudine treatment YMDD positive patient HBV DNA 300 copies/ml decompensated cirrhosis renal failure prior interferon usage evidence HCC prior organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>lamivudine</keyword>
	<keyword>telbivudine</keyword>
	<keyword>adefovir</keyword>
	<keyword>lamivudine resistance</keyword>
</DOC>